LifeArc Venture led a €37m Series A round in Tribune Therapeutics.

LifeArc Venture, a self-financing medical research charity, led a €37m Series A round in Tribune Therapeutics, a biotechnology company, with the participation from Innovator's Life Science Fund, Novo Holdings, Healthcap, Inven2 and Industrifonden. “Advancing our programs towards the clinic with the backing of such a strong and prestigious investor group further increases our confidence in our innovative approach to treat fibrotic diseases, many of which are fatal,” Georg Vo Beiske, Tribune Chief Executive Officer.